These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 29475141)

  • 21. Reversing of multidrug resistance breast cancer by co-delivery of P-gp siRNA and doxorubicin via folic acid-modified core-shell nanomicelles.
    Wu Y; Zhang Y; Zhang W; Sun C; Wu J; Tang J
    Colloids Surf B Biointerfaces; 2016 Feb; 138():60-9. PubMed ID: 26655793
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Celecoxib enhances doxorubicin-induced cytotoxicity in MDA-MB231 cells by NF-kappaB-mediated increase of intracellular doxorubicin accumulation.
    van Wijngaarden J; van Beek E; van Rossum G; van der Bent C; Hoekman K; van der Pluijm G; van der Pol MA; Broxterman HJ; van Hinsbergh VW; Löwik CW
    Eur J Cancer; 2007 Jan; 43(2):433-42. PubMed ID: 17097285
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts.
    Zhong Y; Zhang J; Cheng R; Deng C; Meng F; Xie F; Zhong Z
    J Control Release; 2015 May; 205():144-54. PubMed ID: 25596560
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reversal of P-glycoprotein-mediated multidrug resistance is induced by saikosaponin D in breast cancer MCF-7/adriamycin cells.
    Li C; Guan X; Xue H; Wang P; Wang M; Gai X
    Pathol Res Pract; 2017 Jul; 213(7):848-853. PubMed ID: 28554760
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pegylated phosphotidylethanolamine inhibiting P-glycoprotein expression and enhancing retention of doxorubicin in MCF7/ADR cells.
    Wang J; Qu H; Jin L; Zeng W; Qin L; Zhang F; Wei X; Lu W; Zhang C; Liang W
    J Pharm Sci; 2011 Jun; 100(6):2267-77. PubMed ID: 21246559
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Proteomic analysis of the vitamin C effect on the doxorubicin cytotoxicity in the MCF-7 breast cancer cell line.
    Bober P; Alexovic M; Talian I; Tomkova Z; Viscorova Z; Benckova M; Andrasina I; Ciccocioppo R; Petrovic D; Adamek M; Kruzliak P; Sabo J
    J Cancer Res Clin Oncol; 2017 Jan; 143(1):35-42. PubMed ID: 27620743
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metabolomic Identification of Anticancer Metabolites of Australian Propolis and Proteomic Elucidation of Its Synergistic Mechanisms with Doxorubicin in the MCF7 Cells.
    Alsherbiny MA; Bhuyan DJ; Radwan I; Chang D; Li CG
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360606
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Paclitaxel-doxorubicin sequence is more effective in breast cancer cells with heat shock protein 27 overexpression.
    Shi P; Wang MM; Jiang LY; Liu HT; Sun JZ
    Chin Med J (Engl); 2008 Oct; 121(20):1975-9. PubMed ID: 19080259
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nelfinavir targets multiple drug resistance mechanisms to increase the efficacy of doxorubicin in MCF-7/Dox breast cancer cells.
    Chakravarty G; Mathur A; Mallade P; Gerlach S; Willis J; Datta A; Srivastav S; Abdel-Mageed AB; Mondal D
    Biochimie; 2016 May; 124():53-64. PubMed ID: 26844637
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Multi-Functional Tumor Theranostic Nanoplatform for MRI Guided Photothermal-Chemotherapy.
    Shi J; Wang B; Chen Z; Liu W; Pan J; Hou L; Zhang Z
    Pharm Res; 2016 Jun; 33(6):1472-85. PubMed ID: 26984128
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Breast cancer targeted chemotherapy based on doxorubicin-loaded bombesin peptide modified nanocarriers.
    Wang C; Sun X; Wang K; Wang Y; Yang F; Wang H
    Drug Deliv; 2016 Oct; 23(8):2697-2702. PubMed ID: 26203692
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tanshinone IIA potentiates the chemotherapeutic effect of doxorubicin against breast cancer cells and attenuates the cardiotoxicity of doxorubicin by regulating ERK1/2 pathway.
    Li S; FeiyuTeng ; Zhang J; Zhang P; Li M; Wang X; Li K
    J Biochem Mol Toxicol; 2024 Oct; 38(10):e23851. PubMed ID: 39267350
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The influence of oracin on reduction and toxicity of doxorubicin in hepatocytes and mammary epithelial cells MCF-10A.
    Hanušová V; Boušová I; Pakostová A; Skálová L
    Xenobiotica; 2012 Jun; 42(6):571-9. PubMed ID: 22217270
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Despite Blocking Doxorubicin-Induced Vascular Damage, Quercetin Ameliorates Its Antibreast Cancer Activity.
    Henidi HA; Al-Abbasi FA; El-Moselhy MA; El-Bassossy HM; Al-Abd AM
    Oxid Med Cell Longev; 2020; 2020():8157640. PubMed ID: 33728016
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reversal effect of isotetrandrine, an isoquinoline alkaloid extracted from Caulis Mahoniae, on P-glycoprotein-mediated doxorubicin-resistance in human breast cancer (MCF-7/DOX) cells.
    Wang TX; Yang XH
    Yao Xue Xue Bao; 2008 May; 43(5):461-6. PubMed ID: 18717331
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multifunctional aptamer-based nanoparticles for targeted drug delivery to circumvent cancer resistance.
    Liu J; Wei T; Zhao J; Huang Y; Deng H; Kumar A; Wang C; Liang Z; Ma X; Liang XJ
    Biomaterials; 2016 Jun; 91():44-56. PubMed ID: 26994877
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synergistic anti-cancer effects of silibinin with conventional cytotoxic agents doxorubicin, cisplatin and carboplatin against human breast carcinoma MCF-7 and MDA-MB468 cells.
    Tyagi AK; Agarwal C; Chan DC; Agarwal R
    Oncol Rep; 2004 Feb; 11(2):493-9. PubMed ID: 14719089
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer.
    Gianni L; Viganò L; Locatelli A; Capri G; Giani A; Tarenzi E; Bonadonna G
    J Clin Oncol; 1997 May; 15(5):1906-15. PubMed ID: 9164201
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination of Doxorubicin with Gemcitabine-Incorporated G-Quadruplex Aptamer Showed Synergistic and Selective Anticancer Effect in Breast Cancer Cells.
    Joshi M; Choi JS; Park JW; Doh KO
    J Microbiol Biotechnol; 2019 Nov; 29(11):1799-1805. PubMed ID: 31546295
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular iodine impairs chemoresistance mechanisms, enhances doxorubicin retention and induces downregulation of the CD44+/CD24+ and E-cadherin+/vimentin+ subpopulations in MCF-7 cells resistant to low doses of doxorubicin.
    Bontempo A; Ugalde-Villanueva B; Delgado-González E; Rodríguez ÁL; Aceves C
    Oncol Rep; 2017 Nov; 38(5):2867-2876. PubMed ID: 28901484
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.